**1. Introduction**

Sarcoidosis is a multisystemic granulomatous disorder of unknown etiology [1]. Our understanding of the pathogenesis of sarcoidosis has advanced and provided new insights into potential causes of this disease. It is important to remember that any etiologic agent of sarcoidosis must be capable of causing the pathologic hallmark of systemic noncaseating granulomas and the heterogeneous clinical features of sarcoidosis [2]. It is caused by alteration of the cellular immune response after exposure to an environmental, occupational, or infectious hazard and can involve multiple tissues and organs, including breast tissue [3].

About 80–90% of patients present lung or hiliar lymph nodes affected. These are the most common systems involved. However, the involvement of skin, eyes,

nervous system, locomotor system, lacrimal and salivary glands, heart, and kidney in sarcoidosis has also been described [1].

Sarcoid involvement of the breast parenchyma has been extremely rare in patients with sarcoidosis, less than 1% of the overall diagnosed patients. It is more common in African American, Afro-Caribbean, Swedish, and Danish individuals. It typically presents in women in their third and fourth decade of life and can often mimic breast carcinoma [4].

The descriptions of breast sarcoid vary in the literature from masses with illdefined margins or spiculated as seen in cancer, negative imaging, or other nonspecific appearances [3]. The most common presentation is a palpable breast mass. Because sarcoidosis can mimic breast cancer, it makes the differential diagnosis very difficult [3].
